Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Philipp Lehr is active.

Publication


Featured researches published by Philipp Lehr.


The Journal of Steroid Biochemistry and Molecular Biology | 2000

Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal steroid sulfatase inhibitors

Andreas Billich; Peter Nussbaumer; Philipp Lehr

Steroid sulfatase (STS) regulates the formation of active steroids from systemic precursors, such as estrone sulfate and dehydroepiandrosterone sulfate (DHEAS). In breast tissues, this pathway is a source for local production of estrogens, which support the growth of endocrine-dependent tumours. Therefore, inhibitors of STS could have therapeutic potential. In this study, we report on substituted chromenone sulfamates as a novel class of non-steroidal irreversible inhibitors of STS. The compounds are substantially more potent (6- to 80-fold) than previously described types of non-steroidal inhibitors when tested against purified STS. In MCF-7 breast cancer cells, they inhibit STS activity with IC(50) below 100 pM. Importantly, the compounds also potently block estrone sulfate-stimulated growth of MCF-7 cells, again with IC(50) below 100 pM. For one compound, we also observed a lack of any estrogenic effect at high concentrations (1 microM). We also demonstrate for the first time that STS inhibitors can block the DHEAS-stimulated growth of MCF-7 cells. Interestingly, this cannot be achieved with specific inhibitors of the aromatase, suggesting that stimulation of MCF-7 cell growth by DHEAS follows an aromatase-independent pathway. This gives further justification to consider steroid sulfatase inhibitors as potential drugs in the therapy of breast cancer.


Antiviral Research | 1994

HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization

Andreas Billich; Brigitte Charpiot; Gert Fricker; Hubert Gstach; Philipp Lehr; Peter Peichl; Dieter Scholz; Brigitte Rosenwirth

Derivation of the 2-aminobenzylstatine containing HIV-1 proteinase (PR) inhibitor I led to a series of compounds with considerably improved antiviral activity, the most potent derivatives inhibiting HIV-1 with IC50 values below 25 nM. This was achieved by the combination of several structural modifications, most prominently by introduction of a benzimidazole heterocycle into the inhibitor. The mode of action of the 2-aminobenzylstatine PR inhibitors was demonstrated to be inhibition of gag precursor processing. The antiviral efficacy of the PR inhibitors was demonstrated in various cell lines, in primary T4 lymphocytes and in monocytes. The most potent compound (XI) inhibited replication of several HIV-1 clinical isolates in primary cells with IC50 values of 8 to 23 nM. The analysis of the pharmacokinetic behaviour of compounds I and VII revealed blood half-lives in rodents in the range of about 1.5 h. Compound I also showed appreciable oral uptake in mice (18%), but yielded no detectable blood levels in rats after oral administration. Benzimidazole containing compounds like VII were not orally bioavailable to a significant extent, neither in mice nor in rats. Thus, while introduction of a benzimidazole group into the PR inhibitors was a successful structural modification with regard to antiviral activity in cell culture, it completely abolished oral bioavailability.


Journal of Enzyme Inhibition | 1993

Kinetic and binding studies on [125I]SDZ-283471, a radiolabeled inhibitor of HIV-1 proteinase

Andreas Billich; Alexander Aziz; Philipp Lehr; Brigitte Charpiot; Hubert Gstach; Dieter Scholz

AbstractKinetic and binding studies on a novel type of potent inhibitors of HIV-1 proteinase containing a 2-aminobenzyl substituted statine moiety as dipeptide mimetic are reported. The compounds were characterized as fast-binding competitive inhibitors of the enzyme. Using the radioiodinated derivative [125I]SDZ-283471, monophasic association and dissociation curves were observed indicating a simple bimolecular reaction. While the association rate constant was similar to that of other inhibitors, the dissociation constant of SDZ-283471 was 20–500 times lower. Thus, the enzyme-inhibitor complex appears to be very stable in the case of the 2-aminobenzyl-statine compounds. Furthermore, we demonstrated that the inhibitors show appropriate specificity for HIV-1 and HIV-2 proteinases as compared to other aspartic proteinases. Using a competition assay, relative potencies of inhibitors modified in the P2 position were obtained and a preference for valine at this site was obseived.


Journal of Medicinal Chemistry | 2002

2-Substituted 4-(Thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase

Peter Nussbaumer; Philipp Lehr; Andreas Billich


Journal of Medicinal Chemistry | 1994

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.

Dieter Scholz; Andreas Billich; Brigitte Charpiot; Peter Ettmayer; Philipp Lehr; Brigitte Rosenwirth; Erwin Paul Schreiner; Hubert Gstach


Journal of Medicinal Chemistry | 1996

Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid : Synthesis, activity, and oral bioavailability

Philipp Lehr; Andreas Billich; Brigitte Charpiot; Peter Ettmayer; Dieter Scholz; Brigitte Rosenwirth; Hubert Gstach


Archive | 2006

Inhibitors of Ccr9 Activity

Jose M. Carballido Herrera; Herbert Jaksche; Philipp Lehr; Gudrun Werner; Anthony Winiski


Bioorganic & Medicinal Chemistry Letters | 2003

Nortropinyl-Arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase

Peter Nussbaumer; Dieter Geyl; Amarylla Horvath; Philipp Lehr; Barbara Wolff; Andreas Billich


Bioorganic & Medicinal Chemistry Letters | 2005

N-acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase

Philipp Lehr; Andreas Billich; Barbara Wolff; Peter Nussbaumer


Archive | 2002

Acylsulfonamides as inhibitors of steroid sulfatase

Amarylla Horvath; Philipp Lehr; Peter Nussbaumer; Erwin Paul Schreiner

Collaboration


Dive into the Philipp Lehr's collaboration.

Researchain Logo
Decentralizing Knowledge